Next-Generation Liquid Biopsy Technology Licensed to Epic Sciences
Epic Sciences and USC Michelson Center Convergent Science Institute in Cancer recently announced a new partnership. USC Stevens Center for Innovation helped USC’s Dr. Peter Kuhn with the process of executing the license and collaboration agreement with Epic Sciences.
The license and collaboration agreement gives Epic Sciences exclusive access to the next generation, comprehensive liquid biopsy from Dr. Kuhn’s laboratory and expand Epic’s platform to provide in-depth characterization of both the cell-free fractions and CTCs in the liquid biopsy using genomic, proteomic and AI-based morphological tools, all from a single blood draw.
Read the press release for more information.
–Published November 24, 2020